Clene Inc. · NASDAQ:CLNN
Clene — Technical Presentation (February 2021)
10 slides from Clene's technical presentation, Feb 26, 2021
Slide 1: Effects of Nanocatalysis on CNS Bioenergetic Markers in Patients Treated with CNM-Au8
Robert Glanzman, MD FAAN On behalf of REPAIR - MS Investigators Jimin Ren 1 , Austin Rynders 2 , Benjamin Greenberg 1 , Karen S. Ho 2 , Robert Glanzman 2 , Michael T. Hotchkin 2 1 University of Texas Southwestern Medical Center 2 Clene Nanomedicine, Inc. P 0 4 3 Effects of Nanocatalysis on CNS Bioen
Slide 2: Disclosures
Disclosures I am an employee of Clene Nanomedicine, Inc. and receive salary and stock options 2
Slide 3: CNM-Au8 MoA: Nanocatalytic Electron Transfer
C N M - Au8 | M o A : N a n o c a t a l y t i c E l e c t r o n T r a n s f e r 3
Slide 4: REPAIR: Phase 2 31P-MRS Imaging Study Design
• Difference in average metabolites (e.g., NAD+, NADH) concentration at Week 12 - 16 • Difference in average brain membrane markers (PCr, PME, PE, etc.) at Week 12 - 16 • Pharmacodynamic biomarkers at Week 12 - 16 Change in Brain Bioenergetic Potential (NAD+/NADH) vs. Baseline Visit safety assessmen
Slide 5: REPAIR-MS 31P MRS Imaging Modality
REPAIR - MS | 3 1 P M R S Ima g i n g Mo d a l i t y A T P - - P C r G P E G P C PC PE Pi in Pi ex - NAD UD PG Full Volume Coil Partial Volume Coil Pi in - intracellular inorganic phosphate Pi ex - extracellular inorganic phosphate PC - phosphocholine PE - phosphoethanolamine GPE - glycerophos
Slide 6: REPAIR-MS Baseline Demographics
REPAIR - MS Baseline Demographics 2 7 − J a nu a r y − 2 0 2 1 D a t a U p d a t e Ba s e li ne Values S u bje c ts n (%) Age [ y rs . ] mean (SD) EDSS m e an (SD) Time from MS Onset [yrs.] mean (SD) N ataliz um a b Treatment (%) All 9 (100%) 46.5 (10.8) 3.6 (2.3) 7.2 (5.0) 100% Female 7 39.7 3.0 6.
Slide 7: Percent Change in NAD+/NADH Increases Brain NAD+/NADH Ratio
REPAIR − MS | Percent Change in NAD + /NADH [Partial Volume Coil] CNM - Au8 Increases Brain NAD + /NADH Ratio 7
Slide 8: Normalizes Brain ATP Levels
CNM - Au8 Normalizes Brain ATP Levels Correlation of % Change versus BL value by Subject for Ƒ − ATP & − ATP [Full Volume Coil] 8
Slide 9: Open Label (m)MSFC Clinical Data SDMT & 9HPT
CNM - Au8 Open Label (m)MSFC Clinical Data SDMT & 9HPT 9
Slide 10: Conclusions
Con cl u s io n s • Data demonstrate CNM - Au8 target engagement in brains of MS patients • Catalytic bioenergetic improvements demonstrated across key CNS metabolic markers - NAD+/NADH ratio - ATP ( ߙ , ߛ ) 10